Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EYE103 + anti-VEGF
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Ophthalmic
01
Overview
EYE103 + anti-VEGF refers to a combination therapy where EYE103 (Restoret), an investigational humanized tri-specific antibody designed as a Wnt pathway agonist and norrin mimetic, is used together with an anti-VEGF agent (such as ranibizumab, aflibercept, or similar). EYE103 acts as a Wnt pathway agonist, restoring and maintaining the blood-retinal barrier, resolving residual retinal fluid, and potentially improving visual acuity for conditions like diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD)[1][2]. Anti-VEGF agents inhibit vascular endothelial growth factor (VEGF), thereby suppressing abnormal blood vessel growth and permeability in retinal diseases[5]. The combination aims to address patients who remain refractory to anti-VEGF monotherapy, potentially surpassing the efficacy "ceiling" of anti-VEGF agents alone[1].
- Brand names
- Restoret
- Other names
- EYE103 + anti-VEGF
02
Targets
FZD4 (Frizzled class receptor 4)LRP5 (Low-density lipoprotein receptor-related protein 5)
Beyond the preview
Go deeper on EYE103 + anti-VEGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EYE103 + anti-VEGF.